Picovax (IPV-Al AJV) / AJ Vaccines - LARVOL DELTA

Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine. (PubMed, Vaccine) - P4 | "The present trial demonstrated that the primary vaccination with an aluminium-adjuvanted reduced dose IPV induced a persistent immune memory as evidenced by the robust anamnestic response when the subjects were re-exposed to the antigen 2.5 years after the last dose. Thus, the IPV-Al is an efficient and safe addition to increase the availability of inactivated polio vaccines globally. (ClinicalTrials.gov reg no. NCT04448132)."

Journal

Evaluation of Persistence of Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovax®) (clinicaltrials.gov) - P4; N=163; Completed; Sponsor: AJ Vaccines A/S; Enrolling by invitation ➔ Completed; N=300 ➔ 163; Trial completion date: Mar 2022 ➔ May 2021; Trial primary completion date: Sep 2021 ➔ May 2021

Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease

Evaluation of Persistence of Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovax®) (clinicaltrials.gov) - P4; N=300; Enrolling by invitation; Sponsor: AJ Vaccines A/S; Not yet recruiting ➔ Enrolling by invitation

Clinical • Enrollment open • CNS Disorders • Infectious Disease